Selecta Biosciences Inc (NASDAQ: SELB) and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Selecta shareholders owning
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today
Selecta Biosciences Inc (NASDAQ: SELB) provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the treatment of chronic refractory gout, which Selecta